Lipella Pharmaceuticals Inc. (LIPO)
USD 2.61
(-3.69%)
USD 2.61
(-3.69%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Operating Cash Flow | -3.15 Million | -1.83 Million | -989.27 Thousand | -28.57 Thousand | -39.11 Thousand |
| Net Income | -4.61 Million | -2.59 Million | -1.86 Million | -61.65 Thousand | -61.84 Thousand |
| Depreciation & Amortization | 1685.00 | - | - | - | - |
| Deferred income taxes | -1.52 Million | - | - | - | - |
| Stock-based compensation | 1.47 Million | 747.39 Thousand | 728.79 Thousand | 57.71 Thousand | - |
| Change in working capital | -9108.00 | 9523.00 | 197.6 Thousand | -32.28 Thousand | 14.34 Thousand |
| Other non-cash items | 1.64 Million | 9612.00 | -50.2 Thousand | 7645.00 | 18.72 Thousand |
| Investing Cash Flow | -14.43 Thousand | 300.54 Thousand | -300.54 Thousand | - | - |
| Investments in PPE | -14.43 Thousand | - | - | - | - |
| Acquisitions | - | - | - | - | - |
| Investment purchases | - | 300.54 Million | -300.54 Thousand | - | - |
| Sales/Maturities of investments | - | 300.54 Thousand | - | - | - |
| Other Investing Activities | - | -300.54 Million | -300.54 Thousand | - | - |
| Financing Cash Flow | 1.33 Million | 5.23 Million | 2.09 Million | 609.3 Thousand | 25 Thousand |
| Debt repayment | -275 Thousand | -275.53 Thousand | - | -57.04 Thousand | -25 Thousand |
| Dividends payments | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - |
| Common Stock Issuance | 1.61 Million | 4.96 Million | 2.09 Million | 552.26 Thousand | - |
| Other Financing Activities | 1.21 Billion | 550.53 Thousand | 2.09 Million | 114.08 Thousand | 25 Thousand |
| Accounts receivables | 81.36 Thousand | -113.65 Thousand | 69.03 Thousand | 14.85 Thousand | -43.77 Thousand |
| Accounts payables | -246.34 Thousand | 337.45 Thousand | 22.36 Thousand | -24.8 Thousand | 33.44 Thousand |
| Inventory | - | 113.65 Thousand | -69.03 Thousand | -14.85 Thousand | - |
| Other working capital | 155.86 Thousand | -327.93 Thousand | 175.24 Thousand | -7479.00 | 24.67 Thousand |
| Cash at beginning of period | 5.12 Million | 1.41 Million | 606.73 Thousand | 26 Thousand | 40.12 Thousand |
| Cash at end of period | 3.29 Million | 5.12 Million | 1.41 Million | 606.73 Thousand | 26 Thousand |
| Capital Expenditure | -14.43 Thousand | - | - | - | - |
| Effect of forex changes on cash | -1.82 Billion | - | - | - | - |
| Net cash flow / Change in cash | -1.82 Million | 3.7 Million | 807.09 Thousand | 580.73 Thousand | -14.11 Thousand |
| Free Cash Flow | -3.16 Million | -1.83 Million | -989.27 Thousand | -28.57 Thousand | -39.11 Thousand |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 FY | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | -938.14 Thousand | -1.19 Million | -688.88 Thousand | -4.61 Million | -1.32 Million | -1.53 Million |
| Depreciation & Amortization | 1371.00 | 72.00 | 723.00 | 1685.00 | 962.00 | - |
| Deferred income taxes | - | - | 962.00 | -1.52 Million | -962.00 | - |
| Stock-based compensation | 80.66 Thousand | 208.64 Thousand | -1.35 Million | 1.35 Million | 298.75 Thousand | 847.61 Thousand |
| Change in working capital | -62.68 Thousand | -605.34 Thousand | -41.89 Thousand | -9108.00 | 213.28 Thousand | 41.35 Thousand |
| Other non-cash items | 165.27 Thousand | 289.61 Thousand | 1.35 Million | 1.64 Million | 122.16 Thousand | -5394.00 |
| Investing Cash Flow | - | - | -14.41 Million | -14.43 Thousand | -14.43 Thousand | - |
| Investments in PPE | - | - | -14.41 Million | -14.43 Thousand | -14.43 Thousand | - |
| Acquisitions | - | - | - | - | - | - |
| Investment purchases | - | - | - | - | - | - |
| Sales/Maturities of investments | - | - | - | - | - | - |
| Other Investing Activities | - | - | - | - | - | - |
| Financing Cash Flow | - | 200 Thousand | 1.61 Million | 1.33 Million | -2281.00 | -250 Thousand |
| Debt repayment | - | - | -2348.00 | -275 Thousand | -2281.00 | -250 Thousand |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | - | 200 Thousand | 1.61 Million | 1.61 Million | - | - |
| Other Financing Activities | - | 200 Thousand | 4696.00 | 1.21 Billion | - | -250 Thousand |
| Accounts receivables | 33.6 Thousand | -36.64 Thousand | 20.85 Thousand | 81.36 Thousand | -25.09 Thousand | 55.92 Thousand |
| Accounts payables | -115.47 Thousand | 155.81 Thousand | -165.03 Thousand | -246.34 Thousand | 280.99 Thousand | -126.86 Thousand |
| Inventory | - | - | 60.51 Thousand | - | 25.09 Thousand | -55.92 Thousand |
| Other working capital | 19.19 Thousand | -724.51 Thousand | 41.77 Thousand | 155.86 Thousand | -67.7 Thousand | 168.21 Thousand |
| Cash at beginning of period | 2.1 Million | 3.29 Million | 2.4 Million | 5.12 Million | 3.11 Million | 4.01 Million |
| Cash at end of period | 1.18 Million | 2.1 Million | 3.29 Million | 3.29 Million | 2.4 Million | 3.11 Million |
| Capital Expenditure | - | - | -14.41 Million | -14.43 Thousand | -14.43 Thousand | - |
| Effect of forex changes on cash | - | - | -2281.00 | -1.82 Billion | 2281.00 | - |
| Net cash flow / Change in cash | -918.79 Thousand | -1.18 Million | 883.89 Thousand | -1.82 Million | -703.79 Thousand | -905.1 Thousand |
| Free Cash Flow | -918.79 Thousand | -1.38 Million | -15.14 Million | -3.16 Million | -703.79 Thousand | -655.1 Thousand |
TOP
ANDF
POET
SWEF
ANY
STIE